Toshiba Appoints Rance M. Poehler as President & Chief Executive Officer for Retail Solutions Business
16.11.2020 19:00:00 EET | Business Wire | Press release
Toshiba Global Commerce Solutions today announced Rance M. Poehler is joining the company as its new President and Chief Executive Officer effective November 16, 2020. Poehler has more than 25 years of experience building and expanding business-to-business organizations in unique vertical markets including retail where he has led the development of end-to-end solutions for general retail, quick-service restaurant, hospitality, and other segments. In his role, he will be responsible for leading the company’s continued transformation as a trusted retail commerce solutions leader for its large and growing customer and partner community.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116005083/en/
Rance M. Poehle, President & CEO, Toshiba Global Commerce Solutions (Photo: Business Wire)
Poehler replaces Scott Maccabe who had been appointed President & CEO since 2015. Maccabe is retiring from his role as President & CEO at Toshiba Global Commerce Solutions, while he remains in this capacity at Toshiba America Business Solutions. Poehler takes over effective immediately and will work closely with Maccabe to ensure a full and seamless transition of duties. We thank Scott Maccabe for his commitment, strong leadership and many contributions to the success and growth of the business.
“Rance Poehler is a highly accomplished business executive with a proven track-record for scaling businesses that are in a unique position to transform the industries they serve,” said Maccabe. “Rance brings the fortitude and execution prowess needed to transition the retail business to a full-fledged strategic partner for both customers and partners.”
Poehler joins Toshiba with extensive retail commerce solutions experience and insight. During his tenure as President of Panasonic Systems Communications Company of North America he led a $1.1 billion division morphing it from a product-centric organization to an end-to-end provider of innovative retail solutions in the areas of mobility, point-of-sale, digital signage, computer vision, and analytics that helped Fortune 1000 companies understand shopper demographics and behavior, improve associate engagement and create better customer experiences. While at Dell Technologies he served as vice president of worldwide sales for its cloud client computing team that represents a full suite of cloud and desktop virtualization solutions for retail that enabled scalable thin client solutions. Poehler’s experience also includes Pivot3 where he served as Chief Revenue Officer responsible for leading the global sales organization and executing on the company’s growth strategy and talent acquisition as they developed and went to market with a hyper-converged software platform that manages mixed workloads including IOT-surveillance, analytics, and hybrid cloud solutions.
“The retail industry is looking for new and innovative ways to adapt more quickly to customer needs while they optimize store operations and reduce the cost of delivering and managing their business. Toshiba has a strong worldwide retail position and is on the verge of disrupting the industry with their intelligent end-to-end solutions,” said Poehler. “I’m honored and excited about the opportunity to help this world-class retail commerce solutions business grow in ways that support our partner community, and helps our clients delight their customers while becoming even greater merchants.”
About Toshiba Global Commerce Solutions
Toshiba Global Commerce Solutions is a global market share leader in retail store technology and retail’s first choice for integrated in-store solutions. Together with a global team of dedicated business partners, we achieve brilliant commerce by advancing the future of retail with innovative commerce solutions that enhance customer engagement, transform the in-store experience, and accelerate digital transformation. To learn more, visit commerce.toshiba.com and engage with us on Twitter, LinkedIn, Facebook and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005083/en/
Contact information
Fredrik Carlegren
Vice President of Marketing
(984) 444-2769
fcarlegren@toshibagcs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom